Director’s Bold Move: Major Stock Purchase in SeaStar Medical!

New insider activity at SeaStar Medical Holding ( (ICU) ) has taken place on May 23, 2025.

Director Jennifer A Baird has made a significant investment in SeaStar Medical Holding by purchasing 10,000 shares of the company’s stock, valued at $12,800.

Recent Updates on ICU stock

In the last 24 hours, SeaStar Medical Holding has been in the spotlight due to its recent Q1 2025 earnings report and strategic advancements. The company reported a significant fourfold increase in revenue, driven by the adoption of its QUELIMMUNE therapy, and reached 50% enrollment in its NEUTRALIZE-AKI trial, marking a key milestone. Additionally, SeaStar Medical received two new FDA Breakthrough Device Designations, enhancing its regulatory prospects. Despite these positive developments, challenges such as slow trial enrollment and lengthy IRB approval processes were highlighted as potential obstacles. The company’s strategic focus on expanding its customer base and capturing a share of the $4.5 billion adult AKI market underscores its growth potential. These factors have influenced recent analyst assessments and price target considerations.

Spark’s Take on ICU Stock

According to Spark, TipRanks’ AI Analyst, ICU is a Underperform.

SeaStar Medical Holding faces significant financial challenges, with negative equity and reliance on external financing posing risks to its financial health. Technical indicators show bearish momentum, and valuation metrics highlight ongoing losses, contributing to a low overall stock score.

To see Spark’s full report on ICU stock, click here.

More about SeaStar Medical Holding

YTD Price Performance: -33.33%

Average Trading Volume: 172,345

Technical Sentiment Signal: Sell

Current Market Cap: $13.31M